Chengdu Baiyu Pharmaceutical Co. Ltd. has disclosed pyrrolidine derivatives acting as IL-6 inhibitors and Toll-like receptor 7 (TLR7) and/or TLR8 antagonists reported to be useful for the treatment of autoimmune disease.